January 7, 2025 10:39 AM EST
News Briefing

No­vo Nordisk part­ners with Vari­ant Bio; Avice­da rais­es $207M in Se­ries C

ENDPOINTS

Plus, news about Ale­bund Phar­ma­ceu­ti­cals, Cap­si­da Bio­ther­a­peu­tics, Cy­tomX Ther­a­peu­tics and Gen­er­a­tion Bio:

No­vo Nordisk’s lat­est obe­si­ty part­ner: The Dan­ish phar­ma gi­ant is team­ing up with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

FDA sets an ef­fi­ca­cy thresh­old for fu­ture weight loss drugs

No­vo ex­pands pact with Flag­ship's Va­lo to in­clude obe­si­ty, di­a­betes for $190M near-term

J&J's new can­cer com­bo beats As­traZeneca's Tagris­so on sur­vival in lung tri­al

With schiz­o­phre­nia tri­al suc­cess, LB Phar­ma­ceu­ti­cals thinks about Phase 3 and next fund­ing

A service from the Financial Times